Patent Publication Number: US-2021187105-A1

Title: Combination therapy of anti-mif antibodies and glucocorticoids

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS 
     This application is a Continuation of U.S. application Ser. No. 15/801,260, filed Nov. 1, 2017, which is a Continuation of U.S. application Ser. No. 14/394,709, filed Oct. 15, 2014 (now abandoned), which is a U.S. National Phase of International Application No. PCT/EP2013/057892, filed Apr. 16, 2013, which claims priority to U.S. Provisional Application No. 61/624,988, filed Apr. 16, 2012, U.S. Provisional Application No. 61/668,864, filed Jul. 6, 2012, and U.S. Provisional Application No. 61/785,626, filed Mar. 14, 2013, the disclosures for which are incorporated by reference in their entireties. 
     The present invention pertains to anti-MIF antibodies, in particular their use in combination with glucocorticoids, in the treatment of MIF-related diseases. 
    
    
     BACKGROUND 
     Macrophage migration inhibitory factor (MIF) is a cytokine initially isolated based upon its ability to inhibit the in vitro random migration of peritoneal exudate cells from tuberculin hypersensitive guinea pigs (containing macrophages) (Bloom et al. Science 1966, 153, 80-2; David et al. PNAS 1966, 56, 72-7). Today, MIF is known as a critical upstream regulator of the innate and acquired immune response that exerts a pleiotropic spectrum of activities. The human MIF cDNA was cloned in 1989 (Weiser et al., PNAS 1989, 86, 7522-6), and its genomic localization was mapped to chromosome 22. The product of the human MIF gene is a protein with 114 amino acids (after cleavage of the N-terminal methionine) and an apparent molecular mass of about 12.5 kDa. MIF has no significant sequence homology to any other protein. The protein crystallizes as a trimer of identical subunits. Each monomer contains two antiparallel alpha-helices that pack against a four-stranded beta-sheet. The monomer has additional two beta-strands that interact with the beta-sheets of adjacent subunits to form the interface between monomers. The three subunits are arranged to form a barrel containing a solvent-accessible channel that runs through the center of the protein along a molecular three-fold axis (Sun et al. PNAS 1996, 93, 5191-5196). 
     It was reported that MIF secretion from macrophages was induced at very low concentrations of glucocorticoids (Calandra et al. Nature 1995, 377, 68-71). However, MIF also counter-regulates the effects of glucocorticoids and stimulates the secretion of other cytokines such as tumor necrosis factor TNF-α and interleukin IL-1 R (Baugh et al., Crit Care Med 2002, 30, S27-35). MIF was also shown e.g. to exhibit pro-angiogenic, pro-proliferative and anti-apoptotic properties, thereby promoting tumor cell growth (Mitchell, R. A., Cellular Signalling, 2004. 16(1): p. 13-19; Lue, H. et al., Oncogene 2007. 26(35): p. 5046-59). It is also e.g. directly associated with the growth of lymphoma, melanoma, and colon cancer (Nishihira et al. J Interferon Cytokine Res. 2000, 20:751-62). 
     MIF is a mediator of many pathologic conditions and thus associated with a variety of diseases including inter alia inflammatory bowel disease (IBD), rheumatoid arthritis (RA), acute respiratory distress syndrome (ARDS), asthma, glomerulonephritis, IgA nephropathy, myocardial infarction (MI), sepsis and cancer, though not limited thereto. Polyclonal and monoclonal anti-MIF antibodies have been developed against recombinant human MIF (Shimizu et al., FEBS Lett. 1996; 381, 199-202; Kawaguchi et al, Leukoc. Biol. 1986, 39, 223-232, and Weiser et al., Cell. Immunol. 1985, 90, 16778). 
     Anti-MIF antibodies have been suggested for therapeutic use. Calandra et al., (J. Inflamm. (1995); 47, 39-51) reportedly used anti-MIF antibodies to protect animals from experimentally induced gram-negative and gram-positive septic shock. Anti-MIF antibodies were suggested as a means of therapy to modulate cytokine production in septic shock and other inflammatory disease states. 
     U.S. Pat. No. 6,645,493 discloses monoclonal anti-MIF antibodies derived from hybridoma cells, which neutralize the biological activity of MIF. It could be shown in an animal model that these mouse-derived anti-MIF antibodies had a beneficial effect in the treatment of endotoxin-induced shock. 
     US 200310235584 discloses methods of preparing high affinity antibodies to MIF in animals in which the MIF gene has been homozygously knocked-out. 
     Glycosylation-inhibiting factor (GIF) is a protein described by Galat et al. (Eur. J. Biochem, 1994, 224, 417-21). MIF and GIF are now recognized to be identical. Watarai et al. (PNAS 2000, 97, 13251-6) described polyclonal antibodies binding to different GIF epitopes to identify the biochemical nature of the posttranslational modification of GIF in Ts cells. Watarai et al, supra, reported that GIF occurs in different conformational isoforms in vitro. One type of isomer occurs by chemical modification of a single cysteine residue. The chemical modification leads to conformational changes within the GIF protein. 
     Glucocorticoids, sometimes also named glucocorticosteroids, are a class of steroid hormones that bind to the glucocorticoid receptor, which is present in almost every vertebrate animal. Glucocorticoids are part of the feedback mechanism of the immune system that turns down immune activity, i.e., inflammation. In medicine they are used to treat diseases that are caused by an overactive immune system, whereby exemplary for such diseases are allergies, asthma, autoimmune diseases and sepsis. They also interfere with some of the abnormal mechanisms in cancer cells, so that they are also used to treat cancer. Upon binding the glucocorticoid receptor, the activated glucocorticoid receptor complex up-regulates the expression of anti-inflammatory proteins in the nucleus by a process known as transactivation and represses the expression of pro-inflammatory proteins in the cytosol by attenuating actions on gene induction (via NF-κB, AP1, jun-jun-homodimers etc.). In principle, glucocorticoids are defined as a subgroup of corticosteroids. In addition, a novel class of compounds with glucocorticoid activity (SEGRA, selective glucocorticoid receptor agonists) are known. These compounds exert only some of the actions of full agonistic glucocorticoids, i.e., they fail to elicit the full spectrum of trans-activation, trans-repression and indirect actions on gene induction (via NF-κB, AP1, jun-junhomdimers etc.). By analogy with selective estrogen receptor modulators (SERM&#39;s=tamoxifen, raloxifen, toremifen), these compounds are also referred to as selective glucocorticoid receptor modulators (SERM&#39;s). Examples of SEGRA&#39;s/SEGRM&#39;s include Mapracorate(=BOL303242X=ZK245186), compound A,RU24856, RU24782, RU40066, ZK 216348. 
     An important example of natural glucocorticoids is cortisol (or hydrocortisone) which is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. There are also several synthetic glucocorticoids available. 
     The glucocorticoids act in three major fields, i.e., the immunological, metabolic and foetal development field. In the immune field they upregulate the expression of anti-inflammatory proteins and downregulate the expression of proinflammatory proteins. Metabolic effects can be summarised as follows:
         Stimulation of gluconeogenesis, particularly in the liver: This pathway results in the synthesis of glucose from non-hexose substrates such as amino acids and glycerol from triglyceride breakdown and is particularly important in carnivores and certain herbivores. Enhancing the expression of enzymes involved in gluconeogenesis is probably the best-known metabolic function of glucocorticoids.   Mobilization of amino acids from extrahepatic tissues: These serve as substrates for gluconeogenesis.   Inhibition of glucose uptake in muscle and adipose tissue: The fatty acids released by lipolysis are used for production of energy in tissues like muscle, and the released glycerol provides another substrate for gluconeogenesis.       

     In foetal development glucocorticoids promote maturation of the lung and production of the surfactant which is necessary for extra-uterine lung function. They are further key substances for normal brain development. A variety of synthetic glucocorticoids, some far more potent than cortisol, have been created for therapeutic use. They differ in pharmacokinetics (absorption, half-life, volume of distribution, clearance) and in pharmacodynamics. Glucocorticoid potency, duration of effect, and overlapping mineralocorticoid potency varies. Cortisol (hydrocortisone) is the standard comparison for glucocorticoid potency. Hydrocortisone is the name used for pharmaceutical preparations of cortisol. Oral potency may be less than parenteral potency because significant amounts (up to 50% in some cases) may not be absorbed from the intestine. 
     Examples are:
         Hydrocortisone, Cortisone acetate, cortisone/cortisol, Fluorocortolon, Prednisone, Prednisolone, Methylprednisolone, Triamcinolone, Dexamethasone, Betamethasone, Paramethasone.       

     In addition, there are compounds, which only mimic some but not all actions of glucocorticoids; these compounds are referred to as SEGRAs (selective glucocorticoid receptor agonists). Examples of SEGRA&#39;s/SEGRM&#39;s include Mapracorate(=BOL303242X=ZK245186), compound A,RU24856, RU24782, RU40066, ZK 216348. Steroids mainly for local application (e.g. spray-lung, suppository-colon, cream-skin): Hydrocortisone, Beclomethasone, Budesonide, Fluticasone, Flunisolid, Mometasone, Ciclesonide, Clobetason. 
     It was very surprising to find that macrophage and T-cell MIF production was induced rather than inhibited by glucocorticoids in rodents (Calandra T, Bernhagen J, Metz C N et al., (1995) MIF as a glucocorticoid-induced modulator of cytokine production.  Nature  377:68-71; and Bacher M, Metz C N, Calandra T, et al., (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation.  PNAS  93: 7849-7854). 
     As MIF was known to have pro-inflammatory properties, these results appeared at first paradoxical and difficult to reconcile. Subsequently however it was found that MIF indeed overrides the anti-inflammatory immunosuppressive facts of glucocorticoids. 
     Although glucocorticoids have been shown to be useful and successful in the treatment of several different diseases and disorders (see below), the administration can have a range of side effects, depending on the type of medication used. Most common side effects include
         Immunosuppression   Hyperglycemia due to increased gluconeogenesis, insulin resistance, and impaired glucose tolerance (“steroid diabetes”)   Increased skin fragility, easy bruising   Negative calcium balance due to reduced intestinal calcium absorption   Steroid-induced osteoporosis; reduced bone density (osteoporosis, osteonecrosis, higher fracture risk, slower fracture repair)   Weight gain due to increased visceral and truncal fat deposition (central obesity) and appetite stimulation   Adrenal insufficiency (if used for a long time and stopped suddenly without tapering off)   Muscle breakdown (proteolysis), weakness; reduced muscle mass and repair   Expansion of malar fat pads and dilation of small blood vessels in skin   Anovulation, irregularity of menstrual periods   Growth failure, pubertal delay   Increased plasma amino acids, increased urea formation; negative nitrogen balance   Excitatory effect on central nervous system (euphoria, psychosis)   Glaucoma due to increased cranial pressure   Cataracts       

     The combination of clinical problems produced by prolonged, excess glucocorticoids, whether synthetic or endogenous, is termed Cushing&#39;s syndrome. 
     In addition to the effects listed above, use of high dose steroids for more than a week begins to produce suppression of the patient&#39;s adrenal glands because the exogenous glucocorticoids suppress hypothalamic corticotropin-releasing hormone (CRH) and pituitary adrenocorticotropic hormone (ACTH). With prolonged suppression, the adrenal glands atrophy (physically shrink), and can take months to recover full function after discontinuation of the exogenous glucocorticoid. 
     During this recovery time, the patient is vulnerable to adrenal insufficiency during times of stress, such as illness. Last but not least, patients, who received glucocorticoids over prolonged periods, can also develop glucocorticoid resistance. In these patients, even high doses of glucocorticoids do not suffice to elicit an adequate anti-inflammatory response (Barnes P J, Adcock I M. Glucocorticoid resistance in inflammatory diseases. Lancet 2009 May 30; 373(9678):1905-1917). 
     The side effects listed above increase severely if the dosage of the given glucocorticoid drug is augmented. Decreasing the amount of the drug administered will usually also result in lower or alleviated side effects. 
     Thus, there remains an urgent need in the art for the provision of a therapy for MIF-related diseases and disorders which allows reduction of the administration dose of a given glucocorticoid. 
     DESCRIPTION OF THE INVENTION 
     This object has been solved by the present invention. 
     In particular it could be shown that by a combination therapy of anti-MIF antibodies and a given glucocorticoid a synergistic effect could be detected which would allow treatment of MIF-related diseases with a lower dosage of the glucocorticoid and/or achieving a higher effect with a similar dosage as compared to treating this disease with the glucocorticoid alone. 
     In particular, a treatment by a combination therapy of anti-oxMIF antibodies and a given glucocorticoid could be shown to be associated with a synergistic effect, as described above and exemplified in the examples of the present invention. 
     Elevated MIF levels—i.e., levels of MIF in general—are detected after the onset of various diseases, inter alia after the onset of inflammatory diseases or cancer. However, MIF circulates also in healthy subjects, which makes a clear differentiation difficult. oxMIF, on the contrary, is not present in healthy subjects. oxMIF is increased in disease states and detectable in samples of patients, like e.g. blood, serum and urine. 
     It has been discovered after thorough research of MIF and antibodies thereto that the antibodies RAB9, RAB4 and RAB0 specifically bind to oxMIF (and are incapable of binding to redMIF). This binding is also observed for the antibodies RAM9, RAM4 and RAM0. 
     In earlier experiments carried out by the inventors, it could be shown that oxidative procedures like cystine-mediated oxidation, GSSG (ox. Glutathione)-mediated oxidation or incubation of MIF with Proclin300 or protein crosslinkers (e.g. BMOE) causes binding of MIF to the above-mentioned antibodies. 
     The surprising conclusions reached by the present inventors are:
     Redox modulation (Cystine/GSSG-mediated mild oxidation) of recombinant MIF (human, murine, rat, CHO, monkey)) or treatment of recombinant MIF with Proclin300 or protein crosslinkers leads to the binding of Baxter&#39;s anti-MIF antibodies RAB9, RAB4 and RAB0   Reduction of oxMIF leads to the loss of Ab binding   Specificity for oxMIF-isoforms correlates with biological Ab efficacy in vivo.   oxMIF levels can be correlated with a disease state.   

     This additional knowledge regarding (ox)MIF served as a basis for the further studies of the present inventors. Preferred embodiments of the present invention are: 
     1. An anti-MIF antibody in combination with a glucocorticoid for use in the treatment of a glucocorticoid-receptive disease. 
     2. The anti-MIF antibody in combination with a glucocorticoid according to item 1, where the glucocorticoid receptive disease is responsive to treatment with a glucocorticoid. 
     3. The anti-MIF antibody in combination with a glucocorticoid according to item 1 or 2 for use in the treatment of inflammation, allergy, cancer or asthma. 
     4. The anti-MIF antibody in combination with a glucocorticoid according to item 1, 2, or 3, wherein the antibody is an anti-oxMIF antibody. 
     5. The combination according to any one of items 1-4, wherein the anti-MIF antibody is selected from the following group: anti-MIF antibody RAB9, RAB4, RAB0, RAM9, RAM4 and/or RAM0. 
     6. The combination according to any of items 1 to 5 wherein the glucocorticoid is selected from the group consisting of glucocorticoid receptor agonists, e.g., Methylprednisolone, Prednisolone, Trimacinolone, Dexamethasone, Paramethasone, Fluorcortolone, Budesonide, Fluticasone, Flunisolide, Ciclesonide, Mometasone, Clobetasone, Cortisone and Hydrocortisone, and anti-inflammatory SEGRA&#39;s/SEGRM&#39;s (e.g., Mapracorate(=BOL303242X=ZK245186), compound A, RU24856, RU24782, RU40066, ZK 216348). 
     7. The combination according to any of items 1 to 6, wherein the anti-MIF antibody is either one of antibodies RAB9, RAB4 or RAB0 or RAM9, RAM4 or RAM0, preferably antibody RAM9, the glucocorticoid is selected from the group of (methyl)Prednisolone and Dexamethasone in the case of systemic administration and Budesonide in the case of local administration and the MIF-related disease is inflammation, in particular nephritis, even more preferred lupus nephritis, gomerulonephritis, IgA or IgM nephropathy, systemic vasculitides (e.g., polyarteritis nodosa, Wegener&#39;s granulomatosis and Henoch-Schönlein purpura), anti-GBM nephritis and/or rapidly progressive glomerulonephritis, (type I, II, III or IV), like e.g. ANCA (anti-neutrophil cytoplasmic antibodies)nephritis). 
     8. The combination according to any of items 1 to 6, wherein the anti-MIF antibody is either one of antibodies RAB9, RAB4 or RAB0, or RAM9, RAM4 or RAM0 preferably antibody RAM9, the glucocorticoid is selected from the group of (methyl)Prednisolone and Dexamethasone in the case of systemic administration and Budesonide in the case of local administration and the MIF-related disease is Lupus nephritis. 
     9. The combination according to any of items 1 to 6, wherein the anti-MIF antibody is either one of antibodies RAB9, RAB4 or RAB0, or RAM9, RAM4 or RAM0, preferably RAM9, the glucocorticoid is selected from the group of (methyl)Prednisolone and Dexamethasone in the case of systemic administration and Budesonide in the case of local administration and the MIF-related disease is systemic lupus erythematosus. 
     10. The combination therapy according to any of items 1 to 6, wherein the anti-MIF antibody is either one of antibodies RAB9, RAB4 or RAB0, or RAM9, RAM4 or RAM0, preferably RAM9, the glucocorticoid is selected from the group of Dexamethasone, and (methyl)Prednisolone in the case of systemic administration and Budesonide in the case of local administration and the MIF-related disease is cutaneous inflammation. 
     11. The combination therapy according to any of items 1 to 6, wherein the anti-MIF antibody is either one of antibodies RAB9, RAB4 or RAB0, or RAM9, RAM4 or RAM0, preferably RAM9, the glucocorticoid is selected from the group of Dexamethasone, and (methyl)Prednisolone in the case of systemic administration and Budesonide or hydrocortisone in the case of local administration and the MIF-related disease is caused by a a T-cell mediated immune response. 
     12. The combination therapy of item 10 or 11, wherein the T-cell mediated immune response is cutaneous inflammation, e.g. psoriasis, or contact hypersensitivity. 
     13. The combination therapy of any one of items 10-12, wherein the glucocorticoid is Budesonide and wherein the Budesonide is formulated for topical application. 
     14. The combination therapy as claimed in any of items 1 to 5, wherein the anti-MIF antibody is either one of antibodies RAB9, RAB4 or RAB0, or RAM9, RAM4 or RAM0, preferably RAM9, the glucocorticoid is Budesonide and the MIF-related disease is inflammatory bowel disease(IBD), wherein IBD is selected from ulcerative colitis and Crohn Disease. 
     15. The combination therapy as defined in any of items 1 to 6, wherein the anti-MIF antibody is either one of antibodies RAB9, RAB4 or RAB0, or RAM9, RAM4 or RAM0, preferably RAM9, the glucocorticoid is selected from the group of (methyl)Prednisolone and Dexamethasone in the case of systemic administration and Budesonide in the case of local administration and the MIF-related disease is multiple sclerosis. 
     16. A kit comprising the combination as defined in any of items 1-15 above, and instructions for use. 
     17. A combination as defined in any of items 1-15 above, or the kit of item 16, for use in the treatment of a glucocorticoid receptive disease, in particular inflammation, allergy, asthma or cancer. 
     The above mentioned antibodies are characterized and supported by both their sequences as well as by deposits as plasmids in  E. coli  (strain TG1), comprising either the light or the heavy chain of each of the above mentioned antibodies RAB0, RAB4 and RAB9, respectively and RAM0, RAM4 and RAM9, respectively. 
     The plasmids are characterized by their DSM number which is the official number as obtained upon deposit under the Budapest Treaty with the German Collection of Microorganisms and Cell Cultures (DSMZ), Mascheroder Weg 1b, Braunschweig, Germany. The plasmids were deposited in  E. coli  strains, respectively. 
     The plasmid with the DSM 25110 number comprises the light chain sequence of the anti-MIF antibody RAB4. 
     The plasmid with the DSM 25112 number comprises the heavy chain (IgG4) sequence of the anti-MIF antibody RAB4. 
     The co-expression of plasmids DSM 25110 and DSM 25112 in a suitable host cell results in the production of preferred anti-MIF antibody RAB4. 
     The plasmid with the DSM 25111 number comprises the light chain sequence of the anti-MIF antibody RAB9. 
     The plasmid with the DSM 25113 number comprises the heavy chain (IgG4) sequence of the anti-MIF antibody RAB9. 
     The co-expression of plasmids DSM 25111 and DSM 25113 in a suitable host cell results in the production of preferred anti-MIF antibody RAB9. 
     The plasmid with the DSM 25114 number comprises the light chain sequence of the anti-MIF antibody RAB0. 
     The plasmid with the DSM 25115 number comprises the heavy chain (IgG4) sequence of the anti-MIF antibody RAB0. 
     The co-expression of plasmids DSM 25114 and DSM 25115 in a suitable host cell results in the production of preferred anti-MIF antibody RAB0. 
     Additional plasmids were deposited according to the Budapest Treaty on Apr. 12, 2012 with the DSMZ for the light and heavy chain sequences of RAM0, RAM4 and RAM9, respectively, as following: 
     RAM9 (heavy chain):  E. coli  GA.662-01.pRAM9 hc-DSM 25860. 
     RAM4 (light chain):  E. coli  GA.906-04.pRAM4lc-DSM 25861. 
     RAM9 (light chain):  E. coli  GA.661-01.pRAM9lc-DSM 25859. 
     RAM4 (heavy chain):  E. coli  GA.657-02.pRAM4 hc-DSM 25862. 
     RAM0 (light chain):  E. coli  GA.906-01.pRAM0lc-DSM 25863. 
     RAM0 (heavy chain):  E. coli  GA.784-01.pRAM0hc-DSM 25864. 
     The term “prophylactic” or “therapeutic” treatment is art-recognized and refers to administration of a drug to a patient. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if administered after manifestation of the unwanted condition, the treatment is therapeutic (i.e., it is intended to diminish, ameliorate or maintain the existing unwanted condition or side effects therefrom). 
     As used herein an anti-(ox)MIF compound refers to any agent that attenuates, inhibits, opposes, counteracts, or decreases the biological activity of (ox)MIF. An anti(ox)MIF compound may be an agent that inhibits or neutralizes (ox)MIF activity, for example an antibody, particularly preferred, the antibodies as described herein, even more preferred the antibodies RAB9, RAB4 and/or RAB0 or RAM9, RAM4 or RAM0. 
     The preferred MIF antagonist in accordance with the present invention is an anti-MIF antibody. Even more preferred the anti-MIF antibody is an antibody against oxMIF. In other embodiments, the anti-oxMIF antibodies, e.g. the antibodies mentioned above or an antigen-binding portion thereof bind oxMIF with a K D  of less than 100 nM, preferably a K D  of less than 50 nM, even more preferred with a K D  of less than 10 nM. 
     The invention further relates to kits comprising an anti-MIF antibody or an antigen-binding portion thereof as well as a glucocorticoid agent according to the invention. A kit may include in addition to the antibody and the glucocorticoid agent, further therapeutic agents and uses thereof. A kit also can include instructions for use in a therapeutic method. 
     Earlier results have shown that an anti-MIF antibody that only binds oxMIF and does not bind redMIF and further inhibits GCO and/or cell proliferation induces a beneficial effect in an animal model. 
     DETAILED DESCRIPTION OF THE INVENTION 
     The invention is further described in the figures as enclosed. 
    
    
     
       DESCRIPTION OF THE FIGURES: 
         FIG. 1 : Schematic diagram of dose-finding treatment with Dexamethasone as carried out in Example 1 a. 
         FIG. 2 : Proteinuria on day 8 after administration of several different doses of Dexamethasone. 
         FIG. 3 : Macrophage infiltration after administration of several doses of Dexamethasone. The number of macrophages (ED1 positive cells) per glomerular cross section was determined. The result for each animal as well as the mean for each group is shown. 
         FIG. 4 : Glomerular crescents after several doses of Dexamethasone. The percentage of glomerular crescents determined for each animal is indicated and the mean for each group is shown. 
         FIG. 5 : Schematic diagram of the dose finding for anti-MIF antibody RAM9 in a glycine formulation according to Example 1b. 
         FIG. 6 : Proteinuria on day 8 after two doses of antibody RAM9. 
         FIG. 7 : Macrophage infiltration after two doses of antibody RAM9. The number of macrophages (ED1 positive cells) per glomerular cross section was determined. The result for each animal as well as the mean for each group is shown 
         FIG. 8 : Glomerular crescent formation after two doses of antibody RAM9. The percentage of glomerular crescents determined for each animal is indicated and the mean for each group is shown. 
         FIG. 9 : Schematic diagram of treatment schedule for a combination of Dexamethasone and antibody RAM9 according to Example 1c. 
         FIG. 10 : Reduction of proteinuria after combined treatment with antibody RAM9 (dose range 0-120 mg/kg) and Dexamethasone (0.025 mg/kg). The mean of two independent experiments is depicted. The arrows show the % reduction of proteinuria by different doses of Dexamethasone without application of antibody. 
         FIG. 11 : Observed reduction of macrophage infiltration after combined treatment with antibody RAM9 (dose range 0-120 mg/kg) and Dexamethasone (0.025 mg/kg). The mean of two independent experiments is depicted. The arrows show the % reduction of macrophage infiltration by different doses of Dexamethasone without application of antibody. 
         FIG. 12 : Reduction of crescent formation after combined treatment with antibody RAM9 (dose range 0-120 mg/kg) and Dexamethasone (0.025 mg/kg). The mean of two independent experiments is depicted. The arrows show the % reduction of crescent formation by the different doses of Dexamethasone without application of antibody. 
         FIG. 13 : Contact hypersensitivity (CHS) response to DNFB. Attenuated CHS reaction on the challenged ear of mice treated with anti-MIF (RAM9) in combination with hydrocortisone (+HC) compared with mice treated with RAM9 without application of hydrocortisone (−HC). Isotype control antibody treated mice (with or without topical application of hydrocortisone) were used as negative control. 
     
    
    
     
         
         
           
             Eight mice were used per group and reduced ear contact dermatitis was quantified by measuring the difference of ear thickness between the right (challenged) and the left (non-challenged) ear. 
           
         
       
    
     Definitions and General Techniques 
     Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry described herein are those well known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992), and Harlow and Lane Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1990), which are incorporated herein by reference. 
     “MIF” or “macrophage migration inhibitory factor” refers to the protein, which is known as a critical mediator in the immune and inflammatory response, and as a counterregulator of glucocorticoids. MIF includes mammalian MIF, specifically human MIF (Swiss-Prot primary accession number: P14174), wherein the monomeric form is encoded as a 115 amino acid protein but is produced as a 114 amino acid protein due to cleavage of the initial methionine. 
     “MIF” also includes “GIF” (glycosylation-inhibiting factor) and other forms of MIF such as fusion proteins of MIF. The numbering of the amino acids of MIF starts with the N-terminal methionine (amino acid 1) and ends with the C-terminal alanine (amino acid 115). 
     “oxidized MIF” or oxMIF is defined for the purposes of the invention as an isoform of MIF that occurs by treatment of MIF with mild oxidizing reagents, such as Cystine. As has been shown by the present invention, recombinant oxMIF that has been treated this way comprises isoform(s) of MIF that share structural rearrangements with oxMIF that (e.g.) occurs in vivo after challenge of animals with bacteria. 
     redMIF is defined for the purposes of this invention as reduced MIF and is MIF which does not bind to RAB0, RAB9 and/or RAB4. 
     The anti-oxMIF antibodies described in this invention are able to discriminate between ox and red MIF, which are generated by mild oxidation or reduction, respectively. The anti-oxMIF antibodies are useful to specifically detect oxMIF. Discrimination between these conformers is assessed by ELISA or surface plasmon resonance. Both techniques can be performed as well known to a person skilled in the art and as described below. 
     Assessing differential binding of the antibodies by Biacore. 
     Binding kinetics of oxMIF and redMIF to antibody RAB9 and RAB0 are examined by surface plasmon resonance analysis using a Biacore 3000 System. The antibodies were coated on a CM5 (=carboxymethylated dextran) chip and recombinant MIF protein, pre-incubated with 0.2% Proclin300, were injected. (Proclin300 consists of oxidative isothiazolones that stabilize the oxMIF structure). In native HBS-EP buffer (=Biacore running buffer) without addition of ProClin300, none of the recombinant MIF proteins bound to RAB9, RAB0 or to the reference antibody (irrelevant isotype control antibody) used as negative (background) binding control. 
     In a preferred embodiment, oxMIF is MIF which is differentially bound by antibody RAB9, RAB4 and/or RAB0 or an antigen-binding fragment thereof, meaning that these antibodies do bind to oxMIF while redMIF is not bound by either one of these antibodies. 
     In other embodiments, the anti-oxMIF antibodies, e.g., the antibodies mentioned above or an antigen-binding portion thereof bind oxMIF with a K D  of less than 100 nM, preferably a K D  of less than 50 nM, even more preferred with a K D  of less than 10 nM. In an even more preferred embodiment, the antibodies bind oxMIF with a K D  of less than 5 nM. 
     (Non-)binding of an antibody, e.g. RAB9, RAB4 or RAB0 (to oxMIF or redMIF) can be determined as generally known to a person skilled in the art, examples being any one of the following methods: ELISA with recombinant MIF in its reduced or oxidized state, or surface plasmon resonance using recombinant MIF in its reduced or oxidized state, like the well known Biacore assay, described above. 
     A preferred method for the determination of binding is surface plasmon resonance of an antibody to e.g. rec. 
     (ox)MIF whereupon “binding” is meant to be represented by a K D  of less than 100 nM preferably less than 50 nM, even more preferred less than 10 nM whereas the non-binding to redMIF is characterized by a K D  of more than 400 nM. “Binding” and “specific binding” is used interchangeably here to denote the above. “Differential binding” in the context of this application means that a compound, in particular the antibodies as described herein, bind to oxMIF (e.g., with the K D  values mentioned above) while they do not bind to redMIF (with non-binding again being defined as above). 
     An “antibody” refers to an intact antibody or an antigen-binding portion that competes with the intact antibody for (specific) binding. See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989)) (incorporated by reference). The term antibody includes human antibodies, mammalian antibodies, isolated antibodies and genetically engineered forms such as chimeric, camelized or humanized antibodies, though not being limited thereto. 
     The term “antigen-binding portion” of an antibody refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g.(ox)MIF). Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include e.g.—though not limited thereto—the following: Fab, Fab′, F(ab′)2, Fv, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, antibodies and polypeptides that contain at least a portion of an antibody that is sufficient to confer specific antigen binding to the polypeptide, i.e., ox or redMIF. From N-terminus to C-terminus, both the mature light and heavy chain variable domains comprise the regions FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment of amino acids to each domain is in accordance with the definitions of Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), Chothia et al. J. Mol. Biol. 196:901-917 (1987), or Chothia et al., Nature 342:878-883 (1989). An antibody or antigen-binding portion thereof can be derivatized or linked to another functional molecule (e.g., another peptide or protein). For example, an antibody or antigen-binding portion thereof can be functionally linked to one or more other molecular entities, such as another antibody (e.g., a bispecific antibody or a diabody), a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a linking molecule. 
     The term “K D ” refers here, in accordance with the general knowledge of a person skilled in the art to the equilibrium dissociation constant of a particular antibody with the respective antigen. This equilibrium dissociation constant measures the affinity. The affinity determines how much complex is formed at equilibrium (steady state where association balances dissociation) (here: ox or redMIF and antibody). 
     k a =association rate constant[M −1  s −1 ] 
     k d  =dissociation rate constant[s −1 ] 
     K D  =equilibrium dissociation constant=kd/ka [M] 
     The term “human antibody” refers to any antibody in which the variable and constant domains are human sequences. The term encompasses antibodies with sequences derived from human genes, but which have been changed, e.g. to decrease possible immunogenicity, increase affinity, eliminate cysteines that might cause undesirable folding, etc. The term encompasses such antibodies produced recombinantly in non-human cells, which might e.g. impart glycosylation not typical of human cells. 
     The term “humanized antibody” refers to antibodies comprising human sequences and containing also non-human sequences; in particular, a “humanized antibody” refers to a non-human antibody where human sequences have been added and/or replace the non-human sequences. 
     The term “camelized antibody” refers to antibodies wherein the antibody structure or sequences has been changed to more closely resemble antibodies from camels, also designated camelid antibodies. Methods for the design and production of camelized antibodies are part of the general knowledge of a person skilled in the art. 
     The term “chimeric antibody” refers to an antibody that comprises regions from two or more different species. 
     The term “isolated antibody” or “isolated antigen-binding portion thereof” refers to an antibody or an antigen-binding portion thereof that has been identified and selected from an antibody source such as a phage display library or a B-cell repertoire. 
     The production of the anti-(ox)MIF antibodies according to the present invention includes any method for the generation of recombinant DNA by genetic engineering, e.g. via reverse transcription of RNA and/or amplification of DNA and cloning into expression vectors. In some embodiments, the vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. In some embodiments, the vector is capable of autonomous replication in a host cell into which it is introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). In other embodiments, the vector (e.g. non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors” (or simply, “expression vectors”). 
     Anti-(ox)MIF antibodies can be produced inter alia by means of conventional expression vectors, such as bacterial vectors (e.g., pBR322 and its derivatives), or eukaryotic vectors. Those sequences that encode the antibody can be provided with regulatory sequences that regulate the replication, expression and/or secretion from the host cell. These regulatory sequences comprise, for instance, promoters (e.g., CMV or SV40) and signal sequences. The expression vectors can also comprise selection and amplification markers, such as the dihydrofolate reductase gene (DHFR), hygromycin-B-phosphotransferase, and thymidine-kinase. The components of the vectors used, such as selection markers, replicons, enhancers, can either be commercially obtained or prepared by means of conventional methods. The vectors can be constructed for the expression in various cell cultures, e.g., in mammalian cells such as CHO, COS, HEK293, NSO, fibroblasts, insect cells, yeast or bacteria such as  E. coli.  In some instances, cells are used that allow for optimal glycosylation of the expressed protein. 
     The anti-(ox)MIF antibody light chain gene(s) and the anti-(ox)MIF antibody heavy chain gene(s) can be inserted into separate vectors or the genes are inserted into the same expression vector. The antibody genes are inserted into the expression vector by standard methods, e.g., ligation of complementary restriction sites on the antibody gene fragment and vector, or blunt end ligation if no restriction sites are present. 
     The production of anti-(ox)MIF antibodies or antigen-binding fragments thereof may include any method known in the art for the introduction of recombinant DNA into eukaryotic cells by transfection, e.g. via electroporation or microinjection. For example, the recombinant expression of anti-(ox)MIF antibody can be achieved by introducing an expression plasmid containing the anti-(ox)MIF antibody encoding DNA sequence under the control of one or more regulating sequences such as a strong promoter, into a suitable host cell line, by an appropriate transfection method resulting in cells having the introduced sequences stably integrated into the genome. The lipofection method is an example of a transfection method, which may be used according to the present invention. 
     The production of anti-(ox)MIF antibodies may also include any method known in the art for the cultivation of said transformed cells, e.g., in a continuous or batchwise manner, and the expression of the anti-(ox)MIF antibody, e.g., constitutive or upon induction. It is referred in particular to WO 2009/086920 for further reference for the production of anti-(ox)MIF antibodies. In a preferred embodiment, the anti-(ox)MIF antibodies as produced according to the present invention bind to oxMIF or an epitope thereof. Particularly preferred antibodies in accordance with the present invention are antibodies RAB9, RAB4 and/or RAB0. Alternative preferred antibodies are RAM9, RAM 4 and/or RAM0. 
     The sequences of these antibodies are disclosed in WO 2009/086920; see in addition the sequence list of the present application and the following: 
     
       
         
           
               
               
            
               
                 SEQ ID NO: 1 for the amino acid sequence of the light chain of RAB9: 
                   
               
               
                 DIQMTQSPSS LSASVGDRVT ITCRSSQRIM TYLNWYQQKP GKAPKLLIFV ASHSQSGVPS RFRGSGSETD 
               
               
                   
               
               
                 FTLTISGLQP EDSATYYCQQ SFWTPLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY 
               
               
                   
               
               
                 PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN 
               
               
                   
               
               
                 RGEC, 
               
               
                   
               
               
                 SEQ ID NO: 2 for the amino acid sequence of the light chain of RAB4: 
               
               
                 DIQMTQSPGT LSLSPGERAT LSCRASQGVS SSSLAWYQQK PGQAPRLLIY GTSSRATGIP DRFSGSASGT 
               
               
                   
               
               
                 DFTLTISRLQ PEDFAVYYCQ QYGRSLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY 
               
               
                   
               
               
                 PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN 
               
               
                   
               
               
                 RGEC, 
               
               
                   
               
               
                 SEQ ID NO: 3 for the amino acid sequence of the light chain of RAB0: 
               
               
                 DIQMTQSPGT LSLSPGERAT LSCRASQGVS SSSLAWYQQK PGQAPRLLIY GTSSRATGIP DRFSGSASGT 
               
               
                   
               
               
                 DFTLTISRLQ PEDFAVYYCQ QYGRSLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY 
               
               
                   
               
               
                 PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN 
               
               
                   
               
               
                 RGEC, 
               
               
                   
               
               
                 SEQ ID NO: 4 for the amino acid sequence of the light chain of RAB2: 
               
               
                 DIQMTQSPVT LSLSPGERAT LSCRASQSVR SSYLAWYQQK PGQTPRLLIY GASNRATGIP DRFSGSGSGT 
               
               
                   
               
               
                 DFTLTISRLE PEDFAVYYCQ QYGNSLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY 
               
               
                   
               
               
                 PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN 
               
               
                   
               
               
                 RGEC, 
               
               
                   
               
               
                 SEQ ID NO: 5 for the amino acid sequence of the heavy chain of RAB9: 
               
               
                 EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYSMNWVRQA PGKGLEWVSS 
               
               
                   
               
               
                 IGSSGGTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAGSQ 
               
               
                   
               
               
                 WLYGMDVWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 
               
               
                   
               
               
                 FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT 
               
               
                   
               
               
                 CNVDHKPSNT KVDKRVESKY GPPCPPCPAP EFLGGPSVFL FPPKPKDTLM 
               
               
                   
               
               
                 ISRTPEVTCV VVDVSQEDPE VQFNIMNDGV EVHNAKTKPR EEQFNSTYRV 
               
               
                   
               
               
                 VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP 
               
               
                   
               
               
                 PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 
               
               
                   
               
               
                 SFFLYSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLGK, 
               
               
                   
               
               
                 SEQ ID NO: 6 for the amino acid sequence of the heavy chain of RAB4: 
               
               
                 EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYAMDWVRQA PGKGLEWVSG 
               
               
                   
               
               
                 IVPSGGFTKY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVN 
               
               
                   
               
               
                 VIAVAGTGYY YYGMDVWGQG TTVTVSSAST KGPSVFPLAP CSRSTSESTA 
               
               
                   
               
               
                 ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 
               
               
                   
               
               
                 SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF 
               
               
                   
               
               
                 PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE 
               
               
                   
               
               
                 EQFNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP 
               
               
                   
               
               
                 REPQVYTLPP SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 
               
               
                   
               
               
                 TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL 
               
               
                   
               
               
                 SLGK, 
               
               
                   
               
               
                 SEQ ID NO: 7 for the amino acid sequence of the heavy chain of RAB0: 
               
               
                 EVQLLESGGG LVQPGGSLRL SCAASGFTFS WYAMDWVRQA PGKGLEWVSG 
               
               
                   
               
               
                 IYPSGGRTKY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVN 
               
               
                   
               
               
                 VIAVAGTGYY YYGMDVWGQG TTVTVSSAST KGPSVFPLAP CSRSTSESTA 
               
               
                   
               
               
                 ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 
               
               
                   
               
               
                 SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF 
               
               
                   
               
               
                 PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE 
               
               
                   
               
               
                 EQFNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP 
               
               
                   
               
               
                 REPQVYTLPP SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 
               
               
                   
               
               
                 TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL 
               
               
                   
               
               
                 SLGK, 
               
               
                   
               
               
                 SEQ ID NO: 8 for the amino acid sequence of the heavy chain of RAB2: 
               
               
                 EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYAMDWVRQA PGKGLEWVSG IVPSGGFTKY ADSVKGRFTI 
               
               
                   
               
               
                 SRDNSKNTLY LQMNSLRAED TAVYYCARVN VIAVAGTGYY YYGMDVWGQG TTVTVSSAST KGPSVFPLAP 
               
               
                   
               
               
                 CSRSTSESTA 
               
               
                   
               
               
                 ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 
               
               
                   
               
               
                 SSLGTKTYTC NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF 
               
               
                   
               
               
                 PPKPKDTLMI SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE 
               
               
                   
               
               
                 EQFNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP 
               
               
                   
               
               
                 REPQVYTLPP SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 
               
               
                   
               
               
                 TPPVLDSDGS FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL 
               
               
                   
               
               
                 SLGK, 
               
               
                   
               
               
                 SEQ ID NO: 9 for the amino acid sequence of RAM0hc: 
               
               
                 EVQLLESGGG LVQPGGSLRL SCAASGFTFS WYAMDWVRQA PGKGLEWVSG IYPSGGRTKY ADSVKGRFTI 
               
               
                   
               
               
                 SRDNSKNTLY LQMNSLRAED TAVYYCARVN VIAVAGTGYY YYGMDVWGQ TTVTVSSAST KGPSVFPLAP 
               
               
                   
               
               
                 SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS 
               
               
                   
               
               
                 SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT 
               
               
                   
               
               
                 CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA 
               
               
                   
               
               
                 PIEKTISKAK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN 
               
               
                   
               
               
                 YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK, 
               
               
                   
               
               
                 SEQ ID NO: 10 for the amino acid sequence of RAM0lc: 
               
               
                 DIQMTQSPGT LSLSPGERAT LSCRASQGVS SSSLAWYQQK PGQAPRLLIY GTSSRATGIP DRFSGSASGT 
               
               
                   
               
               
                 DFTLTISRLQ PEDFAVYYCQ QYGRSLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY 
               
               
                   
               
               
                 PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN 
               
               
                   
               
               
                 RGEC, 
               
               
                   
               
               
                 SEQ ID NO: 11 for the amino acid sequence of RAM9hc: 
               
               
                 EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYSMNWVRQA PGKGLEWVSS IGSSGGTTYY ADSVKGRFTI 
               
               
                   
               
               
                 SRDNSKNTLY LQMNSLRAED TAVYYCAGSQ WLYGMDVWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT 
               
               
                   
               
               
                 AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 
               
               
                   
               
               
                 CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE 
               
               
                   
               
               
                 DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA 
               
               
                   
               
               
                 KGQPREPQVY TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK 
               
               
                   
               
               
                 LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK, 
               
               
                   
               
               
                 SEQ ID NO: 12 for the amino acid sequence of RAM9lc: 
               
               
                 DIQMTQSPSS LSASVGDRVT ITCRSSQRIM TYLNWYQQKP GKAPKLLIFV ASHSQSGVPS RFRGSGSETD 
               
               
                   
               
               
                 FTLTISGLQP EDSATYYCQQ SFWTPLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY 
               
               
                   
               
               
                 PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN 
               
               
                   
               
               
                 RGEC, 
               
               
                   
               
               
                 SEQ ID NO: 13 for the amino acid sequence of RAM4hc: 
               
               
                 EVQLLESGGG LVQPGGSLRL SCAASGFTFS IYAMDWVRQA PGKGLEWVSG IVPSGGFTKY ADSVKGRFTI 
               
               
                   
               
               
                 SRDNSKNTLY LQMNSLRAED TAVYYCARVN VIAVAGTGYY YYGMDVWGQG TTVTVSSAST KGPSVFPLAP 
               
               
                   
               
               
                 SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 
               
               
                   
               
               
                 NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED 
               
               
                   
               
               
                 PEVKFNWYVD GVEVHNAKTK 
               
               
                   
               
               
                 PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSREEMTK 
               
               
                   
               
               
                 NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE 
               
               
                   
               
               
                 ALHNHYTQKS LSLSPGK, 
               
               
                   
               
               
                 SEQ ID NO: 14 for the amino acid sequence of RAM4lc: 
               
               
                 DIQMTQSPGT LSLSPGERAT LSCRASQGVS SSSLAWYQQK PGQAPRLLIY GTSSRATGIP DRFSGSASGT 
               
               
                   
               
               
                 DFTLTISRLQ PEDFAVYYCQ QYGRSLTFGG GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY 
               
               
                   
               
               
                 PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN 
               
               
                   
               
               
                 RGEC. 
               
            
           
         
       
     
     The anti-MIF antibody of the invention is preferably an isolated monoclonal antibody. The anti-MIF antibody can be an IgG, an IgM, an IgE, an IgA, or an IgD molecule. In other embodiments, the anti-MIF antibody is an IgG1, IgG2, IgG3 or IgG4 subclass. In other embodiments, the antibody is either subclass IgG1 or IgG4. In other embodiments, the antibody is subclass IgG4. In some embodiments, the IgG4 antibody has a single mutation changing the serine (serine 228) to proline. Accordingly, the CPSC sub-sequence in the Fc region of IgG4 becomes CPPC, which is a sub-sequence in IgG1 (Angal et al. Mollmmunol. 1993, 30, 105-108). 
     Additionally, the production of anti-(ox)MIF antibodies may include any method known in the art for the purification of an antibody, e.g., via anion exchange chromatography or affinity chromatography. In one embodiment the anti-(ox)MIF antibody can be purified by size exclusion chromatography. 
     The terms “center region” and “C-terminal region” of MIF refer to the region of human MIF comprising amino acids 35-68 and aa 86-115, respectively, preferably aa 50-68 and aa 86 to 102 of human MIF, respectively. 
     Particularly preferred antibodies of the present invention bind to either region aa 50-68 or region aa 86-102 of human MIF. This is also reflected by the epitope binding of the preferred antibodies RAB0, RAB4 RAB2 and RAB9 as well as RAM4, RAM0 and RAM9 which bind as follows: 
     RAB4 and RAM4: aa 86-102 
     RAB9 and RAM9: aa 50-68 
     RAB0 and RAM0: aa 86-102 
     RAB2: aa 86 -102 
     Thus, RAM4 and RAB4 have the same specificity, as have RAM9 and RAB9. The same is true for RAM0 and RAB0. This is also reflected by the examples carried out which show that similar results will be obtained with these antibodies. 
     The term “epitope” includes any protein determinant capable of specific binding to an immunoglobulin or an antibody fragment. Epitopic determinants usually consist of chemically active surface groupings of molecules such as exposed amino acids, amino sugars, or other carbohydrate side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. 
     The term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. In some embodiments, the vector is a plasmid, i.e., a circular double stranded DNA loop into which additional DNA segments may be ligated. 
     The term “host cell” refers to a cell line, which is capable to produce a recombinant protein after introducing an expression vector. The term “recombinant cell line”, refers to a cell line into which a recombinant expression vector has been introduced. It should be understood that “recombinant cell line” means not only the particular subject cell line but also the progeny of such a cell line. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “recombinant cell line” as used herein. 
     The host cell type according to the present invention is e.g. a COS cell, a CHO cell or e.g. an HEK293 cell, or any other host cell known to a person skilled in the art, thus also for example including bacterial cells, like e.g.  E. coli  cells. In one embodiment, the anti-MIF antibody is expressed in a DHFR-deficient CHO cell line, e.g., DXB11, and with the addition of G418 as a selection marker. When recombinant expression vectors encoding antibody genes are introduced into CHO host cells, the antibodies are produced by culturing the host cells for a period of time sufficient to allow for expression of the antibody in the host cells or secretion of the antibody into the culture medium in which the host cells are grown. 
     Anti-(ox)MIF antibodies can be recovered from the culture medium using standard protein purification methods. The second active ingredient of the combination therapy as provided by the present invention is a glucocorticoid. Glucocorticoids, sometimes also named glucocorticosteroids, are a class of steroid hormones that bind to the glucocorticoid receptor (Glucocorticoid receptor a), which is present in almost every vertebrate animal. 
     Glucocorticoids are part of the feedback mechanism of the immune system that turns immune activity, i.e. inflammation, down. In medicine they are used to treat diseases that are caused by an overactive immune system, whereby exemplary for such diseases are allergies, asthma, autoimmune diseases and sepsis. They also interfere with some of the abnormal mechanisms in cancer cells, so that they are also used to treat cancer. Upon binding the glucocorticoid receptor, the activated glucocorticoid receptor complex up-regulates the expression of anti-inflammatory proteins in the nucleus by a process known as transactivation and represses the expression of pro-inflammatory proteins in the cytosol. In principle, glucocorticoids are defined as a subgroup of cortico-steroids. In addition, a novel class of compounds with glucocorticoid activity (SEGRA, selective glucocorticoid receptor agonists) are known. 
     These compounds exert only some of the actions of full agonistic glucocorticoids, i.e., they fail to elicit the full spectrum of transactivation, transrepression and indirect actions on gene induction (via NF-κB, AP1, jun-jun homo-dimers etc.). By analogy with selective estrogen receptor modulators (SERM&#39;s=tamoxifen, raloxifen, toremifen), these compounds are also referred to as selective glucocorticoid receptor modulators (SEGRM&#39;s). Examples of SEGRA&#39;s/SEGRM&#39;s include Mapracorate(=BOL303242X=ZK245186), compound A,RU24856, RU24782, RU40066, ZK 216348. All these compounds have been described in the art and are by now well known to the person skilled in the art. See in particular review article De Bosscher et al, 2010, Curr Opin Pharmacol 10: 497-504 for an overview. RU 24856, RU 40066 and RU 24782 are described e.g. in Vayssière et al, 1997, Mol Endocrinol 11:1245-1255. These are the respective chemical formulae: 
     
       
         
         
             
             
         
       
     
     ZK245186 is disclosed in Proksch et al, 2011, Drug Metab Dispos 39:1181-1187 and in Schacke et al., 2009, Br J Pharmacol, 158(4):1088-103. It has the following formula: (R)-1,1,1-Trifluoro-4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-4-methyl-2-{[(2-methyl-5-quinolyl)amino]methyl}pentan-2-ol. ZK 216348 is known from Schacke et al.,2004, PNAS USA 101:227-232. It has the following chemical formula: 
     
       
         
         
             
             
         
       
     
     Compound A is disclosed in Rauner et al, 2011, Endocrinology 152:103-112 as well as in De Bosscher K, Vanden Berghe W, Beck I M, Van Molle W, Hennuyer N, Hapgood J, Libert C, Staels B, Louw A, Haegeman G, 2005, A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA 102:15827-15832. The Compound A has the formula 2-(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride. 
     An important example of a glucocorticoid is cortisol (or hydrocortisone), which is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. There are also several synthetic glucocorticoids available. 
     The glucocorticoids act in three major fields, i.e. the immunological, metabolic and foetal development field. In the immune field they upregulate the expression of anti-inflammatory proteins and downregulate the expression of proinflammatory proteins. Metabolic effects can be summarised as follows:
         Stimulation of gluconeogenesis, particularly in the liver: This pathway results in the synthesis of glucose from non-hexose substrates such as amino acids and glycerol from triglyceride breakdown and is particularly important in carnivores and certain herbivores. Enhancing the expression of enzymes involved in gluconeogenesis is probably the best-known metabolic function of glucocorticoids.   Mobilization of amino acids from extrahepatic tissues: These serve as substrates for gluconeogenesis.   Inhibition of glucose uptake in muscle and adipose tissue: The fatty acids released by lipolysis are used for production of energy in tissues like muscle, and the released glycerol provides another substrate for gluconeogenesis.       

     In foetal development glucocorticoids promote maturation of the lung and production of the surfactant which is necessary for extra-uterine lung function. They are further key substances for normal brain development. 
     A variety of synthetic glucocorticoids, some far more potent than cortisol, have been created for therapeutic use. 
     They differ in pharmacokinetics (absorption factor, half-life, volume of distribution, clearance) and in pharmacodynamics. 
     In the context of the present invention “glucocorticoids” shall mean all glucocorticoids which act at the glucocorticoids receptor alpha. In particular, this encompasses the “classical” glucocorticoid receptor agonists as well as the above described SEGRAs. In a preferred embodiment, all those glucocorticoids are encompassed which act via the NF-κB pathway and/or the AP-1 pathway. In a further preferred embodiment, the inventive glucocorticoids are all (“classical”) glucocorticoids. 
     Theoretically, at some point in time in the future there might be—though unlikely—glucocorticoids which only act e.g. via transactivation or transrepression, but do not act via the NF-κB pathway. In a preferred embodiment, these compounds would not be encompassed by the present invention. 
     NF-κB is nuclear factor kappa light chain enhancer of activated B-cells. It is a specific transcription factor, which exists in practically all cell types and tissues. By binding to particular regulatory regions of the DNA it can influence the transcription of target genes, like anti-apoptotic genes, the caspase-family of genes, and in particular cyclooxygenase-2 (Cox-2), IL-6 and TNF-alpha. 
     Glucocorticoid potency, duration of effect, and overlapping mineralocorticoid potency varies. Cortisol (hydrocortisone) is the standard comparison for glucocorticoid potency. Hydrocortisone is the name used for pharmaceutical preparations of cortisol. Oral potency may be less than parenteral potency because significant amounts (up to 50% in some cases) may not be absorbed from the intestine. 
     Examples of preferred glucocorticoids of the present invention are:
         Hydrocortisone, Cortisone acetate, Cortisone/Cortisol, Fluorocortolon, Prednisone, Prednisolone, Methylprednisolone (particularly for systemic administration), Triamcinolone, Dexamethasone, Betamethasone, Paramethasone, Budesonide (particularly for local administration), SEGRAs (selective glucocorticoid receptor agonists).       

     In addition, there are compounds, which only mimic some but not all actions of glucocorticoids; these compounds are referred to as SEGRAs (selective glucocorticoid receptor agonists). Examples of SEGRA&#39;s/SEGRM&#39;s include Mapracorate(=BOL303242X=ZK245186), compound A, RU24856, RU24782, RU40066, ZK 216348. SEGRAs typically exert their effects via the NFK-B pathway. 
     Steroids mainly for local application (e.g. spray-lung, suppository-colon, cream-skin): Hydrocortisone, Beclomethasone, Budesonide, Fluticasone, Flunisolid, Mometasone, Ciclesonide, Clobetason, most preferably Budesonide. 
     In a further preferred embodiment the glucocorticoid is selected from the group consisting of Hydrocortisone, Cortisone acetate, Budesonide, Fludrocortisone, Dexamethasone, Prednisolone and/or Methylprednisolone. Particularly preferred are (Methyl)prednisolon, Hydrocortisone and Dexamethasone, even more preferred (methyl)Prednisolone for systemic administration. Hydrocortisone can be preferred for a topical application in one embodiment of the invention. In a further preferred embodiment Budesonide is preferred for local administration. Salts, esters and/or isomers of glucocorticoids are all meant to be encompassed in the scope of the present invention and shall be understood to fall under the term “glucocorticoid”. They are all well known or can be prepared by well-known methods. 
     It was very surprising to find that macrophage and T-cell MIF production was induced rather than inhibited by glucocorticoids in rodents (Calandra T, Bernhagen J, Metz C N et al.,(1995) MIF as a glucocorticoid-induced modulator of cytokine production.  Nature  377:68-71; and Bacher M, Metz C N, Calandra T, et al., (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. PNAS 93: 7849-7854). 
     As MIF was known to have pro-inflammatory properties, these results appeared at first paradoxical and difficult to reconcile. Subsequently however it was found that MIF indeed overrides the anti-inflammatory immunosuppressive facts of glucocorticoids. 
     Any given glucocorticoid known by a person skilled in the art can be used in the context of the present invention; these can be the above-mentioned exemplary glucocorticoids. Further, the synthesis of a glucocorticoid again is well-known in the art. 
     Glucocorticoids have been shown to be successful in alleviation and treatment of several diseases. However, most glucocorticoids are associated with a range of side effects, as e.g. described above, which are in some cases extreme, to the extent that the treatment has to be abrogated. In any case, the side effects place a further burden on the physical and mental health of a patient and should thus be avoided as far as possible. 
     With the present invention, by combining a glucocorticoid with an anti-MIF antibody it is now possible to reduce the amount of the glucocorticoid, which is necessary for a given treatment compared to a situation where the glucocorticoid is given as the sole active ingredient. A further possibility enabled by the present invention is to maintain the dose of the glucocorticoid as compared to the glucocorticoid given alone and have a much higher treatment response in the patient. 
     It was shown quite surprisingly by the present inventors that the effect obtained by combining a glucocorticoid with an anti-MIF antibody allowed a clear dose reduction of glucocorticoid while the same treatment response could still be maintained. 
     A treatment response can easily be determined by a person skilled in the art and refers to diminishing or ameliorating or alleviating a given condition. Assays to determine this are well known and can be for example determination of the likelihood or length of survival of a subject having a disease with the likelihood or length of survival in other subjects having the same disease or by determining the change of symptoms within one and the same patient over a period of time. 
     A suitable assay is for example the erythrocyte sedimentation assay; additional assays are those as described in the present examples. Preferred glucocorticoids according to the present invention are Cortisone-acetate, Hydrocortisone, Fludrocortisone, Dexamethasone, Budesonide, Prednisolone and/or Methylprednisolone. Particularly preferred are Methylprednisolon, Hydrocortisone and Budesonide and Dexamethasone. Even more preferred are (methyl)Prednisolone and Dexamethasone for systemic administration and Budesonide for topical administration. 
     Particularly preferred combinations are 
     RAM9 in combination with Dexamethasone, 
     RAM9 in combination with Budesonide, 
     RAM9 in combination with hydrocortisone, 
     RAM9 in combination with Prednisolone or Methylprednisolone, 
     RAM0 in combination with Dexamethasone, 
     RAM4 in combination with Dexamethasone, 
     RAM0 in combination with Budesonide, 
     RAM4 in combination with Budesonide, 
     RAM0 in combination with Prednisolone or Methylprednisolone, 
     RAM4 in combination with Prednisolone or Methylprednisolone, 
     RAM4 in combination with hydrocortisone, 
     RAM0 in combination with hydrocortisone. 
     In a particular preferred embodiment Hydrocortisone and Budesonide is used for topical/local application. It is explicitly pointed out that in the context of the present invention every suitable glucocorticoid is encompassed which is known for the treatment of a particular disease state. Thus, in the most preferred embodiment, the glucocorticoid of the invention is a glucocorticoid which is the respective gold standard treatment for a given disease. 
     The above preferred combinations are used preferably for the treatment of a glucocorticoid receptive disease as defined hereinafter. 
     The present combination therapy is particularly suitable for the treatment of a glucocorticoid receptive disease. “Glucocorticoid receptive disease” in the present context is defined as a disease which responds to glucocorticoid therapy. Diseases which are known to respond to glucocorticoid therapy are as listed below. A person skilled in the art considering the present combination therapy would consider that therapy as soon as confronted with a disease state for which he or she would have considered a treatment with a glucocorticoid. 
     Both inflammatory diseases as well as certain cancer types are well known to be glucocorticoid-receptive diseases. For both types of diseases standard glucocorticoid therapies exist. It is the purpose of the present invention to combine anti-MIF therapy with these standard glucocorticoid therapies. It is possible in some instances to also reduce the standard glucocorticoid dosage, if necessary due to side effects. 
     In a preferred embodiment, the glucocorticoid receptive disease is a disease where a significant improvement of the sedimentation values in the erythrocyte sedimentation assay is observed. A significant improvement is an improvement as considered significant by a person skilled in the art. 
     Particularly preferred diseases which could be treated with the present combination therapy would thus be: Inflammatory diseases, even more preferred, the inflammatory diseases would be those diseases which act via the adaptive immune system (i.e. via B- and T-cells). 
     Even more preferred, the glucocorticoid receptive disease would be an allergic disease, even more preferred an autoimmune disorder. 
     All these diseases are known to be responsive to glucocorticoid therapy. 
     Particularly preferred diseases in the context of the present invention are:
         nephritis, in particular glomerulonephritis, rapidly progressive glomerulonephritis (type I, II, Ill or IV), systemic vasculitides (e.g. polyarteritis nodosa, Wegener&#39;s granulomatosis, Henoch-Schönlein purpura, acute proliferative glomerulonephritis)   Lupus nephritis, ANCA nephritis, anti-GBM nephritis (e.g. Goodpasture disease), IgA nephrophaty, IgM nephropathy,   Lupus erythematosus   T-cell mediated immune responses, e.g. Cutaneous inflammation, like psoriasis or contact hypersensitivity   IBD, like Ulcerative colitis and MorbusCrohn   Multiple sclerosis   Rheumatoid arthritis   Uveitis   Type 2 diabetes mellitus   Bronchial asthma   Contact dermatitis   Psoriasis   Atopic dermatitis   Pancreatitis   Pemphigus   Sjögren&#39;s disease   Behcet disease   Horton&#39;s disease   Scleroderma   polymyositis       

     The synergistic effect has been shown for glucocorticoid receptive diseases in the examples below. The selected models are particularly suitable as the effect is shown for an antigen-antibody reaction which would be mechanistically the same for all diseases listed above. 
     Possible dosage forms which are envisaged by the present application are tablets, capsules, sachets or pills. The granules can be used as such as a preferred dosage form, can be filled into capsules or sachets or can be further compressed into tablets or pills. 
     Further dosage forms which are also encompassed by the present application are drinks or syrups, elixirs, tinctures, suspensions, solutions, hydrogels, films, lozenges, chewing gums, orally disintegrating tablets, mouth-washes, toothpaste, lip balms, medicated shampoos, nanosphere suspensions and microsphere tablets, as well as aerosols, inhalers, nebulisers, smoking or freebase powder forms and dosage forms for topical application like creams, gels, liniments or balms, lotions, ointments, ear drops, eye drops and skin patches. 
     Further encompassed are suppositories which can be used e.g. rectally or vaginally. All these dosage forms are well-known to a person skilled in the art. 
     Preferred dosage forms according to the present invention are oral forms like granules, coated granules, tablets, enteric coated tablets, pellets, suppositories and emulsions. Even more preferred are granules and tablets. Other preferred dosage forms are parenteral or topical dosage forms. A particular preferred route of administration for the anti MIF antibody is a subcutaneous or intravenous application. A preferred route of administration for the glucocorticoid is oral application (e.g. a granule, liquid, sachet or tablet). A further preferred application form for the glucocorticoid is topical application, wherein a topical application can encompass an application to the skin and/or a spray, like a nasal spray or inhaler. A further preferred route of administration for a glucocorticoid is an intravenous application. 
     Several glucocorticoids which are marketed as anti-inflammatory are often topical formulations, such as nasal sprays for rhinitis or inhalers for asthma. These preparations have the advantage of only affecting the targeted area, thereby reducing the side effects or potential interactions. Typical compounds are Beclometasone, Budesonide, Fluticasone, Flunisolide, Clobetasone, Mometasone and Ciclesonide. For asthma, glucocorticoids are administered as inhalants with a metered dose or dry powder inhaler. Thus, such formulations are also preferred embodiments of the present invention. 
     The administration can be by all known routes. 
     The term “combination” or “combination therapy” are used interchangeably here. They refer to a dosing regimen where the anti-MIF antibody is administered together with or sequentially to the glucocorticoid or vice versa. The dosing regime would be typically daily for glucocorticoids and every 2 weeks for the anti-MIF antibody. Preferred dosing regimens are: 
     As explained above, it is possible to administer the anti-MIF antibody together with the glucocorticoid or sequentially. “Together with” in this context means that not more than 10 minutes are between the administration of the anti-MIF antibody and the administration of the glucocorticoid. “Sequentially” means that more than 10 minutes have passed between the administration of the anti-MIF antibody and the administration of the glucocorticoid. The time period can then be more than 10 min., more than 30 minutes, more than 1 hour, more than 3 hours, more than 6 hours or more than 12 hours. 
     Anti-MIF antibody and steroid are principally dosed in a way to ensure that both compounds are present within the body during the same time period (for a certain time span). An anti-MIF antibody has a half life of typically 2-4 weeks, steroids a half life of 6-24 hours. 
     Therefore, the above combination therapy also explicitly encompasses a sequential dosing regimen where the skilled person takes into account the well-known half-life of the respective glucocorticoid in question and the antibody in question. In view of the fact that antibodies generally have a half-life of 2-4 weeks, administration of the antibody in question could be only every 2 weeks, every 3 weeks or once a month. The glucocorticoid to be administered in the inventive combination therapy with such an antibody has in a typical embodiment a half-life of 6-24 h; therefore, administration of the glucocorticoid could be every 5 hours, every 6 hours, three times a day, twice a day or once daily in a typical embodiment. 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 dosaqe dexamethasone - comparison rat/mouse/human 
               
            
           
           
               
               
               
               
            
               
                   
                   
                 corresponding 
                 corresponding human 
               
               
                   
                 dose in rats 
                 dose in mice 
                 dose mg/kg/day 
               
               
                 Steroid 
                 mg/kg/day 
                 mg/kg/day 
                 (mg/adult/day) 
               
               
                   
               
            
           
           
               
               
               
               
            
               
                 Dexamethasone 
                 0.025 
                 0.05 
                 0.0041 (0.25-0.5) 
               
               
                   
                 0.075 
                 0.15 
                 0.012 (0.7-1.5) 
               
               
                   
                 0.25 
                 0.5 
                 0.041 (2.5-5.0) 
               
               
                   
               
            
           
         
       
     
     “The rule of Five”, which is well known to a person skilled in the art of steroids, can be used to calculate dosing schedules between different glucocorticoids, as follows: 1 mg Dexamethasone equals approximately 5 mg Prednisolone, which in turn equals approximately 25 mg Cortisone. 
     The above mentioned “high dose” would be typically given in a case where an acute disorder needs to be treated as effectively as possible. It is typically not given for a longer lasting dosing schedule. 
     Dosing of glucocorticoids, as well as the combined dosing with antibodies, according to the present invention, however, will need to be determined by the practitioner on a case-by-case basis according to the specific disorder to be treated and the particulars of the afflicted subject. 
     Just as an example, which shall by no means be construed as limiting the present invention, there would be typically two options for the treatment of nephritis: 
     1) 500 mg Metylprednisolone/day for 3 days (high dose); followed by orally administered Prednisolone max. 30 mg/day (low dose), OR 
     2) orally administered Prednisolone, max. 60 mg/day (medium dose), which is then reduced over time (which can take up to 6 months). 
     Again, the invention is directed to the person skilled in the art who will determine the necessary dosage of both glucocorticoid and anti-MIF antibody based on his or her knowledge, e.g. based on the respective treatment guidelines, e.g. the NIH guidelines. 
     In a particularly preferred embodiment, the active ingredient would be an ingredient which should be delivered with a controlled, e.g. a delayed release. That is, the orally administratable dosage forms of the present invention comprising such an active ingredient might be provided with a coating. Thus, in a preferred embodiment the present invention is directed to granules with coatings and in particular to granules comprising active ingredients which shall be released in a controlled manner, whereby these granules have a coating. 
     More preferred, this coating is pharmacologically acceptable coating and particularly preferred is an enteric coating, a prolonged release coating or a delayed release coating; all such coatings are well known to a person skilled in the art. 
     A subset of in vivo protective anti-MIF mAbs (e.g. RAB9, RAB4, RAB0, RAM9, RAM4, RAM0), which are directed against the pro-inflammatory cytokine MIF (Macrophage Migration Inhibitory Factor) do not bind to unmodified MIF in its reduced state. By contrast, these mAbs were shown to be highly selective for a redox dependent MIF isoform. 
     A particularly preferred antibody is antibody RAB9. 
     Another particularly preferred antibody is antibody RAB4. 
     Yet another particularly preferred antibody is antibody RAB0. 
     A particularly preferred antibody is antibody RAM9. 
     Another particularly preferred antibody is antibody RAM4. 
     Yet another particularly preferred antibody is antibody RAM0. 
     As is shown by the present invention, the combination therapy proposed here is advantageous in that it results in the very surprising synergistic effect of both components. In view of the enormous side effects encountered by treatment with glucocorticoids, the present invention is highly suitable to provide an alternative treatment which will improve the situation of the patient under treatment. Simultaneously, the reduced side effects will also improve patient compliance which is of great importance in particular in chronic diseases. Finally, the present invention allows the practitioner to increase the results as obtained with high glucocorticoid doses even further, which can be immediately life saving in particular disease states and under particular circumstances. 
     The present invention will be in the following described by way of the examples, whereby the examples shall be considered by no means as limiting the present invention. 
     REFERENCE EXAMPLES 
     A) GCO-Assay for Antibody Screening: 
     A THP1 suspension culture is centrifuged and cells are resuspended in fresh full medium to a cell density of 10 6  cells per ml. This culture is transferred into wells of a 96-wellmicroplate (90 μl/well) and a potential anti-MIF antibody is added to give a final concentration of 75 μg/ml. Each antibody is tested in triplicate. After o/n incubation at 37° C. Dexamethasone is added to give a concentration of 2 nM and after one hour incubation at 37° C. LPS is added (3 ng/ml final concentration). After further six hours incubation at 37° C. the supernatant is harvested and the IL-6 concentrations are determined in a commercially available ELISA. The results of the triplicates are averaged and the percentage of IL-6 secretion is determined in comparison to the control antibodies. Antibodies that result in an IL-6 secretion of less than 75% are evaluated as positive. 
     B) Assay for Determination of IC 50  Values 
     The experimental procedure is carried out as described for the screening assay with the exception that increasing amounts of antibody are used (typically from 1-125 nM). The resultant dose response curve is expressed as % inhibition in comparison to a negative control antibody. This curve is used for calculation of the maximum inhibitory effect of the antibody (% Inh max) and the antibody concentration that shows 50% of the maximum inhibitory effect (IC 50 ). 
     C) Inhibition of Cell Proliferation 
     Serum stimulates secretion of MIF in quiescent NIH/3T3 and MIF in turn stimulates cell proliferation. Antibodies inhibiting this endogenous MIF, therefore, decrease the proliferation of quiescent NIH/3T3 cells. The reduction of proliferation is determined by the incorporation of  3 H-thymidine. 
     1000 NIH/3T3 cells per well are incubated in a 96 well plate over the weekend at 37° C. in medium containing 10% serum. Cells are then starved over night at 37° C. by incubation in medium containing 0.5% serum. The 0.5% medium is removed and replaced by fresh medium containing 10% serum, 75 μg/ml antibody and 5 μ Ci/ml of 3H-thymidine. After 16 hours incubation in a CO 2  incubator at 37° C. cells are washed twice with 150 μl of cold PBS per well. Using a multi-channel pipette 150 μl of a 5% (w/v) TCA solution per well are added and incubated for 30 minutes at 4° C. Plates are washed with 150 μl PBS. Per well 75 μl of a 0.5M NaOH solution with 0.5% SDS are added, mixed and stored at room temperature. Samples are measured in a β-counter by mixing 5 ml of Ultima Gold (Packard) and 75 μl sample solution. Each determination is done in triplicate and the values are compared with the values of the control antibody by a t-test. Antibodies that significantly reduce proliferation (P&lt;0.05) are evaluated as positive. 
     D) Binding Studies: Epitope Determination of Anti-MIF Antibodies 
     Each peptide is diluted in coupling buffer to give a peptide concentration of typically 1 μg/ml added to microplates (NUNC Immobilizer™ Amino Plate F96 Clear) and incubated over night at 4° C. (100 μl/well). As controls recombinant full length MIF and PBS are used. The plate is washed 3 times with 200 μl PBST and antibodies (2-4 μg/ml in PBS) are added (100 μl/well) and incubated for 2 hours at room temperature with gentle shaking. The plate is washed 3 times with 200 μl PBST and detection antibody (e.g. Fc specific anti-human IgG/HRP labeled, Sigma) is added (100 μl/well). After incubation for 1 hour at room temperature with gentle shaking, the plate is washed 3 times with 200 μl PBST. Each well is incubated with 100 μl TMB (3,3′,5,5′-tetramethylbenzidine) solution (T-0440, Sigma) for 30 minutes in the dark. Staining reaction is stopped by adding 100 μl of 1.8 M H 2 SO 4 -solution per well. Samples are measured at 450 nm. 
     E) Affinity Determination of Fab Fragments of Anti-MIF Antibodies by Biacore 
     Typically, 40 RU units of human recombinant MIF are immobilized on a sensor chip with a CM5 (=carboxymethylated dextran) matrix (Biacore). Fab fragments are injected at a concentration range of typically 6-100 nM diluted in HBS-EP. After each cycle the chip is regenerated with 50 mM NaOH+1 M NaCl. Affinities are calculated according to the 1:1 Langmuir model. 
     EXAMPLES 
     Introduction: 
     Therapy of diseases using glucocorticoid drugs is often hampered by severe side effects or a required increase of dosage. In this invention we describe that the effectiveness of glucocorticoid compounds (e.g. Dexamethasone, Hydrocortisone or Prednisolone) can be increased by combination with an anti-oxMIF antibody. Such a combination has the potential to result in an improved therapy of such disorders in comparison to the respective monotherapy and even to prolong the life expectancy of patients significantly. 
     In particular, with the present invention the following is achieved:
         lower doses of glucocorticoids can be given to achieve the same effect with a formerly higher dosage, resulting in less side effects   higher efficacy will be encountered at an identical glucocorticoid dosage   high glucocorticoid dosages can be given if desired and will have an enhanced therapeutic effect       

     Nephritis 
     Example 1 
     Animal Model for Crescentic Glomerulonephritis 
     This model is recognized in the art as predictable to show the effects of the invention. It is suitable to show the effects of the combination therapy over the complete range of diseases which can be subsumed under the above definition of “MIF related diseases” particularly, this model is suitable for the following diseases: Lupus nephritis, anti-GBM nephritis, ANCA nephritis, IgA nephropathy. Dexamethasone is recognized in the art as predictive for a respective glucocorticoid in the treatment of a human. E.g. a preferred glucococorticoid for the treatment of lupus nephritis in a human would be Methylprednisolone.
         The effect of anti-MIF monoclonal antibody (mAb) and its combination with Dexamethasone is examined in immune mediated-nephrotoxic nephritis (NTN) in Wistar Kyoto (WKY) rats. This model has a rapid onset of disease with macrophage infiltration, fibrin deposition and tissue destruction 12. NTN is induced in male WKY rats by single intravenous injection of 0.1 ml rabbit anti-rat glomerular basement membrane serum (day 0). mAb and Dexamethasone is injected intraperitoneally at time points and dosages described below. 24 hour urine samples are collected using metabolic cages before induction of glomerulonephritis and at various time intervals after induction of nephritis for quantification of proteinuria. Sections of renal tissues are frozen for subsequent analysis by immunohistology. Morphology of renal injury is assessed in haematoxylin/eosin (H&amp;E) and periodic acid-Schiff (PAS) stained renal tissue sections. Macrophage is detected by immunoperoxidase technique and using the monoclonal mouse antibody ED1 (Serotec, U C). The animal model was described in detail (Tam F W K, Smith J, Morel D, Karkar A M, Thompson E M, Cook H T, Pusey C D: Development of scarring and renal failure in a rat model of crescentic glomerulonephritis. Nephrol Dial Transplant 14:1658-1666, 1999).       

     Dosing of Anti-MIF Antibody 
     Dose range of anti-MIF antibody for human therapy: 
     0.2-25 mg/kg 
     Preferred dose range for human therapy: 1-10 mg/kg 
     The anti-MIF antibodies are 10× more potent in inhibiting human MIF than mouse or rat MIF based on in vitro assays (chemokinesis assay) and affinity measurements. Therefore, the dose range of the Nephritis experiment (Experiment 1c) of 2-120 mg/kg in the rat corresponds to 0.2-12 mg/kg in the human setting. 
     The enhanced therapeutic effect by combining a MIF antagonist with steroids is demonstrated in a rat model for Crescentic Glomerulonephritis. Different concentrations of Dexamethasone are used in a preliminary experiment to find a suboptimal steroid dose (Example 1 a; a schematic diagram of the experiment is depicted in  FIG. 1 ; results are shown in  FIGS. 2-4 ). In a second preliminary experiment the effectiveness of a MIF antagonist (anti-MIF antibody RAM9) is confirmed (Example 1b). Finally, a suboptimal dose of Dexamethasone is combined with said antibody (Example 1c) and this combination results in a markedly improved reduction of disease parameters. The beneficial effect seen in this combination therapy corresponds to the effect that is achieved by more than 10-fold higher steroid dose. 
     Example 1a: 
     Summary (See also  FIG. 1 )
         Treatment is given 4 days after induction of glomerulonephritis in WKY rats   Severity of renal injury is assessed after collection of urine over night (day 7 to day 8) and after culling the animals on day 8 (see  FIG. 1 )   Single intraperitoneal injection of 0.25 mg/kg Dexamethasone reduces proteinuria by approximately 50% ( FIG. 2 ), glomerular macrophage infiltration by approximately 53%)(FIG. 3) and crescent counts by approximately 25% ( FIG. 5 ).   0.025 mg/kg is determined as suboptimal dexamethasone concentration   0.025 mg/kg is considered as appropriate for studying a potential effect of antibody RAM9       

     Example 1b 
     Summary (See also  FIG. 4 )
         Treatment is given 4 and 6 days after induction of glomerulonephritis in WKY rats   Severity of renal injury is assessed after collection of urine over night (day 7 to day 8) and after culling the animals on day 8 ( FIG. 5 )   Intraperitoneal injection of antibody RAM9 reduces       

     Albuminuria ( FIG. 6  and  FIG. 10 ): 60 mg/kg: approx. 22%, 120 mg/kg: approx. 25% 
     Macrophage infiltration ( FIG. 7  and  FIG. 11 ): 60 mg/kg: approximately 26%, 120 mg/kg: approximately 38% 
     Crescent counts ( FIG. 8  and  FIG. 12 ): 60 mg/kg: approximately 10%, 120 mg/kg: approximately 12%
         Furthermore, MIF, TNFα, and 11-13 are reduced in urine.       

     Example 1c 
     Summary (See  FIG. 9 )
         Treatment is given 4 days (Dexamethasone+antibody) and 6 days (antibody alone) after induction of glomerulonephritis in WKY rats   Severity of renal injury is assessed after collection of urine over night (day 7 to day 8) and after culling the animals on day 8 ( FIG. 9 )   Combination of antibody RAM9 and Dexamethasone shows strong synergistic effects, see  FIGS. 10-12 :       

     Effect of Dexamethasone is apparently enhanced by &gt;10-fold 
     The described animal model exemplifies the beneficial effect of a combination therapy of MIF antagonists and steroids. Steroid treatment has a broad range of therapeutic applications, but shows widespread limitations (side effects at high dosages, steroid resistance, etc.). A combination therapy of steroids and MIF antibodies has the potential to open a broad new treatment opportunity in patients with e.g. inflammatory diseases, infectious diseases or cancer. 
     Example 2 
     The following model uses NZB/NZW F1 mice that are recognized in the art an experimental model for systemic Lupus erythematosus and Lupus nephritis. Treatment of these mice is recognized as being predictable for treatment of Lupus nephritis and systemic Lupus erythematosus. 
     The enhanced therapeutic effect by combining a MIF antagonist with steroids is demonstrated in a mouse model for Lupus Nephritis. Different concentrations of Dexamethasone are used in a preliminary experiment to find a suboptimal steroid dose (Experiment 2a). Finally, a suboptimal dose of Dexamethasone is combined with said antibody (Experiment 2b) and this combination results in a markedly improved reduction of disease parameters. 
     For these experiments adult NZB/NZW F1 hybrid mice are used. These mice develop an immunologic disorder that closely resembles systemic Lupus erythematosus (SLE) in man. In the female mice the disease manifests itself by about 32-38 weeks of age with persistent proteinuria and circulating antibodies against nucleic acids. 
     Example 2a 
     “Dose finding of Dexamethasone in NZB/NZW F1 hybrid mice” 
     The goal is to determine a suboptimal dose of Dexamethasone for further synergy studies between steroid therapy and anti MIF antibodies. 
     The establishment of the disease in the NZB/NZW F1 mice is monitored and confirmed by measuring proteinuria. 
     When mice show proteinuria, animals are treated i.p. with different doses of Dexamethasone or vehicle. At the end of the experiment animals are sacrificed and read out parameters are proteinuria, number of glomerular macrophages and renal histology. 
     Group 1: Vehicle 
     Group 2: Dexamethasone 0.5 mg/kg 
     Group 3: Dexamethasone 1.0 mg/kg 
     Group 4: Dexamethasone 2.0 mg/kg 
     Group 5: Histology control 
     Example 2b: 
     “Synergy between anti MIF RAM9 antibody and suboptimal dexamethasone dose in NZB/NZW F1 hybrid mice” With this experiment the synergistic effect between the drug candidate RAM9 antibody and a suboptimal dose of Dexamethasone is investigated. The establishment of the disease in the NZB/NZW F1 mice is monitored and confirmed by measuring proteinuria. When mice show proteinuria, animals are treated with steroid and antibody. At the end of the experiment animals are sacrificed and read-out parameters are proteinuria, number of glomerular macrophages and renal histology. 
     “Groups of Animals” 
     Group 1: Histology control 
     Group 2: Control antibody BAX C3 
     Group 3: Anti MIF RAM9 
     Group 4: Dexamethasone+control antibody BAX C3 
     Group 5: Dexamethasone+anti MIF RAM9 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 Overview Experiment 2 
               
            
           
           
               
               
               
               
            
               
                   
                 Experiment 2 
                 Antibody 
                 Steroid 
               
               
                   
                   
               
               
                   
                 Lupus nephritis 
                 — 
                 Dexamethasone dose 
               
               
                   
                   
                   
                 titration 
               
               
                   
                 Lupus nephritis 
                 RAM9 
                 Dexamethasone 
               
               
                   
                   
               
            
           
         
       
     
     T-Cell Mediated Diseases 
     Example 3a 
     The animal model used is directed to an induction of delayed-type hypersensitivity (DTH) responses to DNFB (2,4-Dinitrofluorbenzol): 057B1/6 mice are sensitized by topical application of DNFB on the abdomen. Mice are challenged by painting DNFB solution onto the mouse ears. Severity of the inflammatory responses is judged by caliper measurements of the ear thickness at 24 h after challenge. At the same time, animals are sacrificed and ears are cut off, and preserved for subsequent histological analyses. 
     This animal model is recognized in the art as predictive for diseases related to T-cell mediated immune responses, e.g. cutaneous inflammation, like psoriasis. 
     The treatment schedule is as follows: 
     T=0d: sensitize mice 
     T=5d: administer anti-inflammatory therapy and challenge mice. 
     T=6d: quantify ear-swelling, sacrifice mice, collect ears for further histological analyses
         The experiments are carried out with the above described model to do a Dexamethasone dose titration (similarly as explained in examples 1 and 2) and to determine the effects of a combination of RAM9 antibody and Hydrocortisone (topic application).       

     All experiments show a synergistic effect of the combination. 
     Example 3b-d 
     Contact hypersensitivity 
     Material and Methods 
     The Contact hypersensitivity (CHS) response to 2,4-dinitrofluorobenzene (DNFB) was determined using a modification of an earlier model described (see Ludwig, et al., 2010,  Am J Pathol  176, 1339-1345). C57BL/6 mice were sensitized by treating the shaved mouse back skin with 75 μl of DNFB (Sigma, St. Louis, Mo.) solution (0.5% in acetone/olive oil, 4/1). On day 5, mice were treated with topical application of hydrocortisone (on challenged ears) or vehicle (on non-challenged ears) and intravenous injection of anti-MIF antibody RAM9 or isotype control antibody. 30 min later the right ears of the mice were challenged with 20 μl 0.3% DNFB to cause a local inflammatory response. The vehicle (acetone/olive) oil was applied to the left ears as a control. The swelling response to DNFB, specified as the difference between the right and left ears, was measured 24 h after challenge using a micrometer (Mitutoyo Co., Tokyo, Japan). 8 mice were used per group. 
     Results 
     Example 3b 
     Dose Titration of Hydrocortisone 
     In a first experiment, three different doses of hydrocortisone (0.3%, 1% and 3% in DAC base cream ointment) were applied without application of antibody. Vehicle without hydrocortisone served as negative control. 1% hydrocortisone was found to be a concentration yielding sub-optimal anti-inflammatory effects in the contact dermatitis model, as determined by measuring ear thickness. 
     Example 3c 
     Dose Titration of Anti-MIF Antibody RAM9 
     In a second experiment, 20 mg/kg anti-MIF antibody RAM9 was applied without hydrocortisone and an isotype control antibody was used as a negative control. Ear swelling, the primary measure in these experiments, was reduced significantly in anti-MIF-treated mice compared with mice treated with an isotype-control antibody or saline. As 20 mg/kg was a highly effective dose, 10 mg/kg RAM9 was used as a sub optimal dose for the subsequent experiment. 
     Example 3d 
     Combined Application of RAM9 (i.v.) and Hydrocortisone (Topical) 
     Finally, mice were treated with 10 mg/kg isotype control antibody or RAM9 alone or in combination with hydrocortisone (1% in DAC base cream). Results are shown in  FIG. 13 . Isotype control antibody treated mice showed an ear swelling of approximately 100 μm. Topical application of a suboptimal dose of hydrocortisone in combination with the isotype control antibody did not reduce ear swelling. 10 mg/kg RAM9 as monotherapy gave also a similar result as the isotype control antibody. However, thickness of the ears was markedly reduced in the group receiving both, RAM9 and hydrocortisone, and a synergistic effect of both drugs in minimization of ear swelling can be concluded. 
     CONCLUSION 
     In summary, these experiments show evidence for a therapeutic synergy of suboptimal doses of RAM9 and hydrocortisone in a mouse model for contact dermatitis.